COBALT is a clinical trial, which aims to find out if adding Memantine to a cholinesterase inhibitor (either donepezil, rivastigmine and galantamine) improves overall health and functioning for people with Dementia with Lewy Bodies (DLB) or Parkinson’s Disease Dementia. (PDD)
The trial is sponsored by Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust and funded by the Health Technology Assessment | NIHR The HTA programme funds research about the clinical and cost effectiveness, and the broader impact of healthcare treatments for those who plan, provide and receive care from the NHS, and social care services.
Preparation for the trial began in 2021 and we will recruit participants from 2022 to 2024
The trial is managed by Newcastle Clinical Trials Unit, a fully registered UK Clinical Research Collective UKCRC Clinical Trials Unit.
A similar study will also be taking place in Australia and at the end of both studies the findings will be shared to help understand whether Memantine treatment when added to a cholinesterase inhibitor help people with DLB or PDD is helpful.
Please explore the headings above to find out more about COBALT, where it is taking place and who can participate.
The views and opinions expressed on this website are those of the authors and do not necessarily reflect those of the HTA, NIHR, NHS or the Department of Health.